Form 4: EXAS CEO Conroy Accelerates RSU Vesting Ahead of Abbott Merger

Exact Sciences CEO Kevin Conroy accelerated the vesting of performance-based restricted share units, totaling 713,931 shares, in connection with a pending merger with Abbott Laboratories to mitigate tax impacts.

Summary

• Kevin T. Conroy, President and CEO of Exact Sciences Corp (EXAS), reported transactions on December 23, 2025.
• Conroy acquired a total of 713,931 shares of Common Stock through the accelerated vesting of performance-based restricted share units (RSUs).
• These RSUs were granted on February 24, 2023 (244,931 shares), February 26, 2024 (138,326 shares), and February 24, 2025 (330,674 shares).
• The vesting acceleration was undertaken to mitigate potential impacts of Sections 280G and 4999 of the Internal Revenue Code in connection with a pending merger.
• The pending merger is contemplated by an Agreement and Plan of Merger, dated November 19, 2025, by and among Exact Sciences Corp, Abbott Laboratories, and Badger Merger Sub I, Inc.
• Conroy disposed of a total of 335,549 shares of Common Stock at a price of $101.82 per share for tax withholding purposes related to the net-settlement of the RSU vesting.
• Following these transactions, Conroy directly beneficially owns 1,234,970 shares of Common Stock.
• Conroy also indirectly beneficially owns 28,806 shares in a 401(k) Plan and 250,715 shares across three Grantor Retained Annuity Trusts.
• In addition to the 1,514,491 shares reported, Conroy holds an aggregate of 663,578 vested and unvested options and restricted stock units.

Sentiment

Score: 5

Explanation: The filing is a factual report of insider transactions driven by a corporate event (merger) and tax planning. It does not inherently convey positive or negative sentiment about the company's operational performance, but the underlying merger could be seen as positive.

Positives

• Acceleration of RSU vesting for the CEO, indicating the achievement of performance conditions or a strategic decision to vest.
• The transactions are a direct consequence of a pending merger with Abbott Laboratories, which could be a positive strategic development for Exact Sciences.
• Proactive mitigation of potential tax impacts under Sections 280G and 4999 of the Internal Revenue Code.

Negatives

• Significant disposition of shares (335,549 shares) for tax withholding purposes, which reduces the CEO's direct ownership post-vesting.

Risks

• Potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986 on the Issuer and certain employees, which the accelerated vesting aims to mitigate.
• The pending merger with Abbott Laboratories carries inherent risks associated with integration, regulatory approvals, and market reception, though not explicitly detailed as risks in this Form 4.

Future Outlook

The accelerated vesting of performance-based restricted share units is directly linked to a pending merger between Exact Sciences Corp and Abbott Laboratories, indicating an expectation for the merger to proceed. The company is also proactively addressing potential tax implications related to this transaction.

Industry Context

This filing highlights a significant corporate event for Exact Sciences, a pending merger with Abbott Laboratories. Such mergers are common in the healthcare and diagnostics industry as companies seek to consolidate market share, expand product portfolios, and achieve synergies. The proactive tax mitigation strategy suggests careful planning around executive compensation in the context of a major transaction.

Corporate Governance

Stakeholder Impact

• Shareholders: The pending merger with Abbott Laboratories, which is the underlying reason for these transactions, could significantly impact shareholder value. The proactive tax mitigation may be viewed positively as prudent financial management.
• Employees: The mention of mitigating tax impacts for "certain of its employees" suggests broader implications for other executives or key personnel involved in the merger.

Next Steps

• Completion of the pending merger between Exact Sciences Corp and Abbott Laboratories.
• Continued management of tax implications related to the merger and executive compensation.

Key Dates

Keywords

EXAS, Exact Sciences, Kevin Conroy, Form 4, Insider Transaction, Restricted Share Units, RSU Vesting, Abbott Laboratories, Merger, Acquisition, Executive Compensation, Section 280G, Tax Mitigation